Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF
Adult
Aged
Clonidine
/ administration & dosage
Cyprus
/ epidemiology
Cytochrome P-450 CYP1A2
/ drug effects
Drug Interactions
Female
Humans
Male
Middle Aged
Mutation
Neoplasm Metastasis
/ drug therapy
Neoplasm Staging
Neoplasms
/ blood
Parasympatholytics
/ administration & dosage
Protein Kinase Inhibitors
/ administration & dosage
Proto-Oncogene Proteins B-raf
/ drug effects
Republic of Korea
/ epidemiology
Vemurafenib
/ administration & dosage
CYP1A2
drug-drug interactions
pharmacokinetics
tizanidine
vemurafenib
Journal
Clinical pharmacology in drug development
ISSN: 2160-7648
Titre abrégé: Clin Pharmacol Drug Dev
Pays: United States
ID NLM: 101572899
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
10
12
2019
accepted:
06
02
2020
pubmed:
21
4
2020
medline:
10
8
2021
entrez:
21
4
2020
Statut:
ppublish
Résumé
This phase 1 open-label, multicenter, 3-period, fixed-sequence study evaluated the effect of multiple doses of vemurafenib on the pharmacokinetics of 1 dose of tizanidine, a probe CYP1A2 substrate, in patients with BRAF
Substances chimiques
Parasympatholytics
0
Protein Kinase Inhibitors
0
Vemurafenib
207SMY3FQT
tizanidine
6AI06C00GW
CYP1A2 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP1A2
EC 1.14.14.1
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Clonidine
MN3L5RMN02
Types de publication
Clinical Trial, Phase I
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
651-658Informations de copyright
© 2020, The American College of Clinical Pharmacology.
Références
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAFv600E and BRAFv600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323-332.
Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-1876.
Ascierto P, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248-1260.
Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4(3):384-388.
Grippo JF, Zhang W, Heinzmann D, et al. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. Cancer Chemother Pharmacol. 2014;73(1):103-111.
Ribas A, Zhang W, Chang I, et al. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014;54(4): 368-374.
Zhang W, Heinzmann D, Grippo JF. Clinical pharmacokinetics of vemurafenib. Clin Pharmacokinet. 2017;56(9):1033-1043.
Zhang W, McIntyre C, Forbes H, et al. Effect of rifampicin on the pharmacokinetics of a single dose of vemurafenib in patients with BRAF(V600) mutation-positive metastatic malignancy. Clinical Pharmacol Drug Dev. 2019;8(6):837-843.
Zhang W, McIntyre C, Kuhn M, et al. Effect of vemurafenib on the pharmacokinetics of a single dose of digoxin in patients with BRAF(V600) mutation-positive metastatic malignancy. J Clin Pharmacol. 2018;58(8):1067-1073.
Sridhar J, Goyal N, Liu J, Foroozesh M. Review of ligand specificity factors for CYP1A subfamily enzymes from molecular modeling studies reported to-date. Molecules. 2017;22(7). https://doi.org/10.3390/molecules22071143.
Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev. 2010;42(2):268-354.
Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009;11(3):481-494.
Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol. 2004;57(3):349-353.
Granfors MT, Backman JT, Neuvonen M, Ahonen J, Neuvonen PJ. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther. 2004;75(4):331-341.
Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther. 2004;76(6):598-606.
Momo K, Homma M, Osaka Y, Inomata S, Tanaka M, Kohda Y. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2010;50(3):331-337.
Backman JT, Karjalainen MJ, Neuvonen M, Laitila J, Neuvonen PJ. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol. 2006;62(3):345-357.
Backman JT, Schroder MT, Neuvonen PJ. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol. 2008;64(1):17-24.
Chen X, Wang L, Zhi L, et al. The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin Pharmacol Ther. 2005;78(3):249-259.
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAFV600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.